Patents Assigned to Eliem Therapeutics (UK) Ltd
  • Compositions that preferentially potentiate subtypes of GABAreceptors and methods of use thereof
    Patent number: 11571432
    Abstract: The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of ?4?3? GABAA receptors over ?1?2?2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: February 7, 2023
    Assignee: Eliem Therapeutics (UK) Ltd
    Inventors: Andrew D. Levin, Neil Buckley